IDEXX Laboratories, Inc. (IDXX) posted second-quarter 2024 earnings per share (EPS) of $2.44, down 8.6% year over year. The figure missed the Zacks Consensus Estimate by 14.9%. Comparable constant-currency EPS of $3.02 improved 14.8% year over year. Revenues in Detail Quarterly revenues increased 6.4% year over year (up 7% organically) to $1.00 billion. The reported figure was in line with the Zacks Consensus Estimate. The year-over-year upside was primarily driven by a strong improvement in Companion Anima ...

For the quarter ended June 2024, Idexx Laboratories (IDXX) reported revenue of $1 billion, up 6.4% over the same period last year. EPS came in at $2.44, compared to $2.67 in the year-ago quarter. The reported revenue represents a surprise of +0.11% over the Zacks Consensus Estimate of $1 billion. With the consensus EPS estimate being $2.87, the EPS surprise was -14.98%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine thei ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.44 per share, missing the Zacks Consensus Estimate of $2.87 per share. This compares to earnings of $2.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.98%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.68 per share when it actually produced earnings of $2.81, delivering a surprise of 4.85%. Ov ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results · Achieves second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics recurring revenue growth of 6% as reported and 7% organic. · Solid growth supported by continued benefits from IDEXX execution drivers, including record second quarter premium instrument placements and double-digit year-over-year global premium instrument installed ...

In its upcoming report, Idexx Laboratories (IDXX) is predicted by Wall Street analysts to post quarterly earnings of $2.87 per share, reflecting an increase of 7.5% compared to the same period last year. Revenues are forecasted to be $1 billion, representing a year-over-year increase of 6.2%. The consensus EPS estimate for the quarter has undergone a downward revision of 1.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their i ...

WESTBROOK, Maine, July 30, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today published its 2023 Corporate Responsibility Report "Enhancing the Health and Well-being of Pets, People, and Livestock for 40 Years" highlighting progress against its corporate responsibility goals. The Care We Advance IDEXX brings clarity to the complex world of veterinary medicine through diagnostic insights and software solutions that support longer, fuller lives fo ...

IDEXX Laboratories, Inc. (IDXX) is set to release second-quarter 2024 results on Aug 6, before the opening bell. Q2 Estimates The Zacks Consensus Estimate for earnings is pinned at $2.87 per share, which implies a 7.5% rise from the year-ago reported figure. Estimates for IDEXX's second-quarter earnings have moved south by a marginal 0.3% to $2.87 per share in the past seven days. In the second quarter, IDXX's Companion Animal Group ("CAG") Diagnostics recurring revenues are expected to have maintained the ...

Pet Owners Worldwide Continue to Prioritize Pet Healthcare ~95% of Pet Owners Indicate They Brought >80% of Pet Owners Would Reduce Spend Their Pet to the Veterinarian When Sick in 2023" on Other Categories to Prioritize Care for a Sick Pet" Moreover, because of better care availability, pets tend to live longer. This comes with increasing costs. The same goes for humans, which is why an aging population is a huge tailwind for many human-focused diagnostics companies. As we can see below, new capabilities h ...

IDEXX Laboratories, Inc. (IDXX) has been facing uncertain macroeconomic conditions. Currency headwinds continue to dent profit. The stock carries a Zacks Rank #4 (Sell) currently. During the first quarter of 2024, foreign exchange had a limited impact on the gross margin, operating profit and earnings. IDEXX's updated 2024 revenue forecast includes a $35 million impact, equivalent to about a 1% decrease, due to the recent appreciation of the U.S. dollar. Key Picks Estimates for Medpace's 2024 earnings per s ...

IDEXX Laboratories, Inc. (IDXX) recently launched the Catalyst Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes. The latest development is likely to strengthen IDEXX's Companion Animal Group ("CAG") Diagnostics business. Significance of the New Test Pancreati ...